证券代码：300841 证券简称：康华生物 公告编号：2023-059 成都康华生物制品股份有限公司 关于持股 5%以上股东及其一致行动人股份减持比例 达到 1%的公告 持股 5%以上的股东青岛盈科盛道创业投资基金合伙企业（有限合伙）及其 一致行动人淄博泰格盈科创业投资中心（有限合伙）保证向本公司提供的信息 内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 成都康华生物制品股份有限公司（以下简称"公司"）于 2023 年 8 月 15 日收到股东青岛盈科盛道创业投资基金合伙企业（有限合伙）（曾用名：平潭 盈科盛道创业投资合伙企业(有限合伙)，以下简称"青岛盈科"）、淄博泰格 盈科创业投资中心（有限合伙）（以下简称"泰格盈科"）出具的《关于股份 减持情况的告知函》，青岛盈科、泰格盈科于 2023 年 8 月 7 日至 2023 年 8 月 15 日通过集中竞价、大宗交易的方式累计减持股份比例达到公司总股本（已剔 除公司最新披露的回购专用账户中的股份）的 1.00%。根据《上市公司收购管 理办法》、《深圳证券交易所上市公司股东及董事、监 ...

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2023-005 ■特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 1. 天风证券 李妞妞 2. 东吴证券 于彦秋 3. 廪实基金 吕 松 4. 廪实基金 秦 盛 5. 普尔投资 刘 祯 参与人员姓名及单位名称 6. 博普资产 申文海 7. 汇森投资 庞雨东 8. 中欧基金 叶培培 9. 国海证券 杨 龙 时间 2023 年 7 月 6 日、7 日 地点 公司会议室 公司接待人员姓名 副总裁、董事会秘书：陆皓 IR 工作人员：何涤沙 投资者关系活动主要内容 介绍 详见会议纪要 日期 2023 年 7 月 10 日 成都康华生物制品股份有限公司 接待机构投资者调研活动的会议纪要 编号：2023-005 1. 公司上半年业绩情况如何？ 就已经披露的 2023 年一季度情况而言，公司实现营业收入 27,811.40 万元， 同比增长 4.27%；归属于上市公司股东的净利润 10,519.06 万元，同比减少 22.24%， 主要系公司今年一季度 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥278,114,028.88, representing a 4.27% increase compared to ¥266,736,074.86 in the same period last year[4]. - Net profit attributable to shareholders decreased by 22.24% to ¥105,190,616.53 from ¥135,277,246.77 year-on-year[4]. - The basic earnings per share decreased by 21.94% to ¥0.7865 from ¥1.0076 in the same period last year[4]. - The total comprehensive income attributable to the parent company was CNY 105,190,616.53, a decrease of 22.2% compared to CNY 135,277,246.77 in the previous period[54]. - Net profit for the period was ¥11,698,408.06, a decrease from ¥20,857,091.39, reflecting a decline of approximately 43.5%[68]. - The company's total profit amounted to ¥116,889,024.59, down from ¥156,134,338.16, showing a decrease of around 25.1%[68]. - The profit attributable to the parent company's owners was ¥105,190,616.53, down from ¥135,277,246.77, a decline of approximately 22.2%[68]. Cash Flow - The net cash flow from operating activities improved significantly by 115.11%, reaching ¥16,892,087.59 compared to a negative cash flow of ¥111,805,582.88 in the previous year[4]. - The net cash flow from operating activities for Q1 2023 was ¥16,892,087.59, a significant improvement of 115.11% compared to the net cash flow of -¥111,805,582.88 in the same period last year[39]. - The company's cash flow from operating activities was positively impacted by an increase in sales scale and collection of receivables during the reporting period[39]. - Cash flow from operating activities rose significantly to ¥264,625,524.15 compared to ¥166,590,278.00, indicating an increase of about 58.8%[69]. Expenses and Costs - Research and development expenses increased by 131.58% to ¥48,657,680.12 from ¥21,011,414.14 in the same period last year, indicating a focus on innovation[21]. - Total operating costs increased to ¥166,597,332.57 from ¥120,171,079.04, representing a growth of approximately 38.5%[68]. - Sales expenses increased to ¥78,388,151.54 from ¥68,683,500.63, which is an increase of approximately 14.8%[68]. - Management expenses rose to ¥22,181,067.10, up from ¥19,138,952.77, reflecting an increase of about 15.9%[68]. - The company reported a financial expense of -¥1,722,386.08, improving from -¥5,294,864.03, indicating a reduction in financial costs[68]. Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,750,403,965.88, a 1.06% increase from ¥3,711,065,217.69 at the end of the previous year[4]. - The total liabilities amounted to CNY 568,940,998.03, down from CNY 635,397,264.58, representing a decrease of 10.5%[67]. - The company's equity attributable to shareholders rose by 3.44% to ¥3,181,462,967.85 from ¥3,075,667,953.11 year-on-year[4]. - The total equity attributable to the parent company increased to CNY 3,181,462,967.85 from CNY 3,075,667,953.11, showing a growth of 3.4%[67]. - The company reported a significant reduction in contract liabilities by 63.88%, down to ¥84,517.47 from ¥233,998.33[6]. - The company reported a decrease in employee compensation payable from CNY 28,300,512.77 to CNY 10,459,512.57, a reduction of 63.0%[67]. Other Information - The first quarter report was not audited, indicating that the figures presented are preliminary and subject to change[31]. - The company has not disclosed any new product or technology developments in the current report[59]. - There were no significant mergers or acquisitions reported during the period[59]. - The company has not indicated any major market expansion strategies in the current report[59]. - The company confirmed that there are no restatements or adjustments required for previous accounting data[58].

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2023-004 | 投资者关系活动类别 | | □特定对象调研 | | □分析师会议 | | --- | --- | --- | --- | --- | | | □媒体采访 | | | ■业绩说明会 | | | □新闻发布会 □路演活动 | | | | | | □现场参观 □其他 | | | | | 参与人员姓名及单位名称 | 参与公司 2022 | | | 年度网上业绩说明会的投资者 | | 时间 | 年 月 2023 | 4 | 14 | 日（星期五）15:00-17:00 | | 地点 | 全景网"投资者关系互动平台" | | | | | 公司接待人员姓名 | 董事长、总裁：王振滔 | | | | | | 副总裁、财务负责人：吴文年 | | | | | | 副总裁、董事会秘书：陆皓 | | | | | | 独立董事：方小波 | | | | | | 保荐代表人：陈耀 | | | | | 投资者关系活动主要内容 | 详见会议纪要 | | | | | 介绍 | | | | | | 日期 | 2023 年 月 ...

证券代码：300841 证券简称：康华生物 公告编号：2023- 出席本次说明会的人员有：公司董事长、总裁王振滔先生，副总裁、财务负 责人吴文年先生，副总裁、董事会秘书陆皓先生，独立董事方小波先生，保荐代 表人陈耀先生（如有特殊情况，参与人员可能进行调整）。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于2023年4月 13日（星期四）14:00前访问http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征 集专题页面，公司将在2022年度业绩说明会上，对投资者普遍关注的问题进行回 答。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 029 成都康华生物制品股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整、没有虚 假记载、误导性陈述或重大遗漏。 成都康华生物制品股份有限公司（以下简称"公司"）《2022年年度报告》 及其摘要已于2023年3月30日在中国证券监督管理委员会指定的创业板信息披露 网站巨潮资讯网（http://w ...

Group 1: Company Performance - In 2022, the company achieved a revenue of 1,446.72 million CNY, representing a year-on-year growth of 11.94% [3] - The net profit attributable to shareholders was 545.13 million CNY, a decrease of 1.83% compared to the previous year [3] - The company issued 8.10 million doses of freeze-dried human rabies vaccine, an increase of 68.84% year-on-year, with a 100% pass rate [3] Group 2: Research and Development - R&D investment in 2022 was 179.94 million CNY, a significant increase of 128.13%, accounting for 12.44% of total revenue [4] - The company has established multiple innovative vaccine platforms, including mRNA and recombinant protein VLP vaccine platforms [5] - The six-valent norovirus vaccine has received approval for Phase I clinical trials in Australia [5] Group 3: Market Strategy and Sales - In 2022, the company sold 5.31 million doses of vaccines, supported by enhanced professional sales capabilities and digital marketing strategies [7] - The company plans to strengthen brand building and increase market coverage in 2023 [7] - The strategic focus includes maintaining leadership in the human diploid rabies vaccine market while advancing innovative vaccine projects [8] Group 4: Challenges and Future Outlook - The decrease in net profit was primarily due to reduced fair value gains from associates and increased R&D expenditures [4] - The six-valent norovirus vaccine addresses unmet clinical needs, presenting significant market potential [6] - The company aims to provide high-quality vaccine products to meet urgent clinical demands and contribute to public health [8]

Financial Performance - Chengdu Kanghua Biological Products Co., Ltd. reported a cash dividend of 5 RMB per 10 shares for all shareholders, with no bonus shares issued[5]. - The company's operating revenue for 2022 was CNY 1,446,724,761.50, an increase of 11.94% compared to CNY 1,292,447,990.55 in 2021[24]. - The net profit attributable to shareholders decreased by 27.90% to CNY 598,066,216.17 from CNY 829,477,810.74 in the previous year[24]. - The net cash flow from operating activities increased by 49.62% to CNY 194,990,553.03, up from CNY 130,325,659.99 in 2021[24]. - The total assets at the end of 2022 reached CNY 3,711,065,217.69, representing a 22.96% increase from CNY 3,018,041,385.96 at the end of 2021[24]. - The basic earnings per share decreased by 27.56% to CNY 4.4652 from CNY 6.1638 in 2021[24]. - The company recorded a total of CNY 52,932,528.92 in non-recurring gains and losses for 2022, down from CNY 274,187,334.45 in 2021[29]. - The company's total equity attributable to shareholders increased by 15.18% to CNY 3,075,667,953.11 at the end of 2022[24]. - The company achieved operating revenue of 1,446.72 million yuan, a year-on-year increase of 11.94%[39]. - The net profit attributable to the parent company was 598.07 million yuan, a year-on-year decrease of 27.90%[39]. - The gross profit margin for the main product, freeze-dried human rabies vaccine (human diploid cells), was 93.75% in 2022, with a year-on-year increase of 10.37%[57]. Research and Development - R&D investment reached 179.94 million yuan, an increase of 128.13% year-on-year[40]. - The company launched 9 R&D projects, with the six-valent norovirus vaccine obtaining Phase I clinical trial approval in Australia in February 2023[40]. - The company completed the upgrade of its R&D center, enhancing its R&D capabilities[43]. - The company has a dedicated R&D team of 117 members, including 8 PhDs, and has implemented a multi-faceted R&D incentive mechanism to boost innovation[50]. - The company is currently developing a vaccine for multiple genotypes of norovirus, which is in the clinical research phase[65]. - The company has initiated clinical research for a meningococcal ACYW135 vaccine, aiming for market launch after completing preclinical studies[66]. - The total R&D investment for 2022 was ¥179,941,306.14, accounting for 12.44% of operating revenue[66]. - The company plans to launch several new vaccines, including a quadrivalent nasal spray flu vaccine and a rabies mRNA vaccine, which are currently in preclinical research[66]. Market and Industry Trends - The company operates in the rapidly growing vaccine manufacturing industry, which has seen significant support for new vaccine development globally[34]. - The global human vaccine market size grew from approximately $27.7 billion in 2017 to about $46 billion in 2021, with a compound annual growth rate (CAGR) of 13.5%[35]. - By 2025, the global human vaccine market is expected to reach approximately $83.1 billion and $131 billion by 2030[35]. - The domestic rabies vaccine market has seen major breakthroughs, including the introduction of Vero cell rabies vaccines and the launch of a human diploid cell rabies vaccine in 2014[36]. - Recent regulatory changes have strengthened vaccine circulation channels and supervision, including the implementation of the Vaccine Administration Law in December 2019[36]. - The "14th Five-Year" plan emphasizes the development of innovative vaccine products and the enhancement of vaccine supply systems[37]. - Major global players like Merck, GSK, Pfizer, and Sanofi Pasteur dominate the vaccine market, while Moderna and BioNTech are emerging as new leaders with mRNA technology[38]. - The domestic vaccine market is fragmented, with state-owned enterprises leading the immunization planning vaccine market and intense competition in non-immunization planning vaccines[38]. Corporate Governance - The company has established a comprehensive governance structure, including a board of directors and supervisory board, to oversee its operations[4]. - The board of directors consists of 7 members, including 3 independent directors, ensuring a diverse range of expertise[103]. - The company strictly adheres to corporate governance standards, ensuring compliance with laws and regulations, and has established a sound internal management and control system[102]. - The company ensures timely and accurate information disclosure, allowing all shareholders equal access to information[106]. - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, and business operations[107]. - The company has a well-structured corporate governance framework, including a shareholder meeting, board of directors, and supervisory board, ensuring independent operational management[111]. - The company has implemented a performance evaluation and incentive mechanism for senior management, ensuring transparency and compliance with legal standards[104]. - The internal audit system is in place, with an audit committee responsible for overseeing internal and external audits[104]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[160]. - The company obtained a pollution discharge permit on July 26, 2020, valid for three years[160]. - The company reported no exceedance of pollutant discharge limits for chemical oxygen demand, ammonia nitrogen, and total phosphorus[161]. - The wastewater treatment facility employs advanced technologies, including ultraviolet light purification and activated carbon adsorption, to manage emissions[161]. - The company has established an emergency response plan for environmental incidents, filed with local authorities in April 2021[162]. - The company has invested approximately 3 million yuan in the construction of a wastewater treatment station, with a monthly operating cost of about 10,000 yuan[166]. - The company has upgraded its vaccine production capacity and replaced its boiler to reduce nitrogen emissions[166]. Employee Management and Development - The company has a long-term development philosophy that emphasizes a performance-based compensation system, linking employee income to corporate performance[143]. - The training program includes internal and external training, focusing on industry knowledge, management skills, and operational training to enhance employee capabilities[145]. - The company has established a training organization system to ensure effective implementation of employee training across all levels[144]. - The company has a total of 793 employees receiving compensation, including retirees[142]. - The company has implemented an employee stock ownership plan and a stock incentive plan for core talents, with a total of 25 core talents involved[151]. Strategic Initiatives and Future Outlook - The company plans to expand its market presence and is focusing on new product development to enhance its competitive edge in the industry[117]. - Chengdu Kanghua announced a strategic initiative to increase its investment in research and development, aiming for a budget allocation of 15% of total revenue for 2023[117]. - The company is also exploring potential mergers and acquisitions to accelerate growth and diversify its product offerings in the coming years[117]. - The management provided guidance for 2023, projecting a revenue growth rate of 25% based on current market trends and product pipeline[117]. - The company aims to increase its production capacity by 50% by the end of 2023 to meet rising demand[183]. - Chengdu Kanghua is committed to sustainability, with plans to reduce carbon emissions by 30% over the next five years[184].

成都康华生物制品股份有限公司 投资者关系活动记录表 股票简称：康华生物 证券代码：300841 编号：2020-006 | --- | --- | --- | --- | |------------------------|----------------------------|--------------|-------| | | | | | | | ■ 特定对象调研 □分析师会议 | | | | | □ 媒体采访 □业绩说明会 | | | | 投资者关系活动类别 | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 □其他 | | | | | 1 、中泰证券 江琦 | | | | | 2 、东方自营 李峰 | | | | | 3 、中融基金 柯海东 | | | | | | | | | | 4 、南土资产 许智涵 | | | | 参与人员姓名及单位名称 | 5 、国寿安保基金 刘志军 | | | | | 6 、太平资产 周烨 | | | | | 7 、太平资产 闵东旭 | | | | | 8 、安信基金 池陈森 | | | | | 9 、华物投资 霍辰伊 | | | | 时间 | 2020 年 ...